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Background
Chronic Myeloid Leukemia (CML) is a clonal myeloproli-
ferative disorder characterized by formation of BCR-ABL
fusion that encodes the p210 oncoprotein, which has a tyr-
osine kinase activity that confers an adaptive advantage to
leukemic cells. Imatinib mesylate (IM) acts specifically on
p210. Imatinib is able to reduce the differentiated cells
(CD66b+) efficiently, but it has not the same effect on the
stem cells (CD34+), which can be kept alive during treat-
ment. Our aim was to identify expressed genes in CD34+
and CD66b+ cells as candidates for kinase inhibitors
transport.
Materials and methods
CD34+ and CD66b+ cells were isolated from bone mar-
row (BM) and peripheral blood (PB) of five patients with
CML, in optimal response, and 1 control. The samples
were sequenced on SOLiDTM platform for whole tran-
scriptome analysis. We analyzed the Gene Ontology anno-
tation, and the software Cufflinks were used to identify the
differential expression of genes in patients (BM x PB) and
controls (BM x PB).
Results
In pooled patient samples, we identified the expression of
SLC22A1 influx gene in both, BM and PB samples, with-
out any significant change (p ≤ 0,05), and expression of
SLCO1A2 influx gene only in PB sample. Thus its pre-
sence could not be identified in any of the control samples.
The overexpression of ABC efflux gene family (ABCB1;
ABCG2; ABCC1), were found only in BM cells of patients.
The presence of other two genes responsible for the drug
efflux was also found exclusively in BM pool sample of
patients, SLC47A1 and SLC47A2.
Conclusions
Over-representation of drug influx and absence of drug
efflux channels in mature cells, and the reverse in stem
cells of patients with CML may explain the insensitivity of
CD34+ cells to IM treatment and consequent failure to
eliminate minimal residual disease.
Financial support
Novartis Oncology of Brazil.
Author details
1Institute of Biological Science, University Federal of Pará. Belém-Pará, Brazil.
2Center of Hemotherapy and Hematology of Pará – HEMOPA Foundation.
Belém-Para, Brazil. 3Department of Hematology - Ophir Loyola Hospital.
Belém-Para, Brazil. 4Department of Genetics, School of Medicine of Ribeirão
Preto, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.
Published: 4 April 2013
doi:10.1186/1753-6561-7-S2-O1
Cite this article as: Moreira-Nunes et al.: Differentially expressed genes
responsible for insensitivity of CD34+ cells to kinase inhibitors in
patients with chronic myeloid leukemia. BMC Proceedings 2013
7(Suppl 2):O1.
* Correspondence: carolfam@gmail.com
1Institute of Biological Science, University Federal of Pará. Belém-Pará, Brazil
Full list of author information is available at the end of the article
Moreira-Nunes et al. BMC Proceedings 2013, 7(Suppl 2):O1
http://www.biomedcentral.com/1753-6561/7/S2/O1
© 2013 Moreira-Nunes et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
